Testing for Acquired Color Vision Deficiencies in Patients Receiving Hydroxychloroquine (Plaquenil) Therapy

Lynn Cyert

doi:10.1364/ACV.1992.FB17

Advances in Color Vision
Technical Digest Series (Optica Publishing Group, 1992),
paper FB17
•https://doi.org/10.1364/ACV.1992.FB17

Testing for Acquired Color Vision Deficiencies in Patients Receiving Hydroxychloroquine (Plaquenil) Therapy

Lynn Cyert

Advances in Color Vision 1992

Irvine, California United States
31 January–1 February 1992
ISBN:

From the session
Poster Session 1 (FB)

Not Accessible

Your library or personal account may give you access

Get PDF
Email
Share
Get Citation
Copy Citation Text
L. Cyert, "Testing for Acquired Color Vision Deficiencies in Patients Receiving Hydroxychloroquine (Plaquenil) Therapy," in Advances in Color Vision, Technical Digest Series (Optica Publishing Group, 1992), paper FB17.

Export Citation
- BibTex
- Endnote (RIS)
- HTML
- Plain Text
Citation alert
Save article

Abstract

Hydroxychloroquine sulfate--trade name Plaquenil--is an antimalarial therapeutic agent derived from chloroquine. Hydroxychloroquine is also important for its use as an anti-inflammatory agent in the treatment of rheumatoid arthritis and discoid and systemic lupus erythematosus(1).

PDF Article

More Like This

Improving color vision for color deficient patients on video displays

Gabor Kovács, György Ábrahám, Itala Kucsera, and Klára Wenzel
FF6 Vision Science and its Applications (VSIA) 2000

Color vision sensitivity screening before and one week after cataract removal surgery

Zane Jansone-Langina and Maris Ozolinsh
126271K European Conference on Biomedical Optics (ECBO) 2023

Assessment of Color Vision Anomalies with the VEP

Michael A. Crognale, Eugene Switkes, Jeff Rabin, Gunilia Haegerstrom-Portnoy, and Anthony J. Adams
SuC3 Noninvasive Assessment of the Visual System (NAVS) 1992

Previous Article Next Article